Literature DB >> 2021529

Has the MOPP era ended?

G P Canellos.   

Abstract

Mesh：

Year:  1991        PMID： 2021529      PMCID： PMC1972342          DOI： 10.1038/bjc.1991.115

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  10 in total

1.  Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy.

Authors:  A Santoro; G Bonadonna; P Valagussa; R Zucali; S Viviani; F Villani; A M Pagnoni; V Bonfante; R Musumeci; F Crippa
Journal:  J Clin Oncol       Date:  1987-01       Impact factor: 44.544

2.  Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results.

Authors:  G Bonadonna; P Valagussa; A Santoro
Journal:  Ann Intern Med       Date:  1986-06       Impact factor: 25.391

3.  ChlVPP chemotherapy in advanced Hodgkin's disease.

Authors:  J J McKendrick; G M Mead; J Sweetenham; D H Jones; C J Williams; R Ryall; J M Whitehouse
Journal:  Eur J Cancer Clin Oncol       Date:  1989-03

4.  Combination chemotherapy in the treatment of advanced Hodgkin's disease.

Authors:  V T Devita; A A Serpick; P P Carbone
Journal:  Ann Intern Med       Date:  1970-12       Impact factor: 25.391

5.  Twenty years of MOPP therapy for Hodgkin's disease.

Authors:  D L Longo; R C Young; M Wesley; S M Hubbard; P L Duffey; E S Jaffe; V T DeVita
Journal:  J Clin Oncol       Date:  1986-09       Impact factor: 44.544

6.  Chlorambucil, vinblastine, procarbazine, and prednisone. An effective but less toxic regimen than MOPP for advanced-stage Hodgkin's disease.

Authors:  B J Druker; D S Rosenthal; G P Canellos
Journal:  Cancer       Date:  1989-03-15       Impact factor: 6.860

7.  Absence of treatment-induced second neoplasms after ABVD in Hodgkin's disease.

Authors:  P Valagussa; A Santoro; F Fossati Bellani; F Franchi; A Banfi; G Bonadonna
Journal:  Blood       Date:  1982-03       Impact factor: 22.113

8.  A combination of chlorambucil, vinblastine, procarbazine and prednisolone for treatment of Hodgkin's disease.

Authors:  T J McElwain; J Toy; E Smith; M J Peckham; D E Austin
Journal:  Br J Cancer       Date:  1977-08       Impact factor: 7.640

9.  An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV Hybrid program.

Authors:  P Klimo; J M Connors
Journal:  Semin Hematol       Date:  1988-04       Impact factor: 3.851

10.  ChlVPP combination chemotherapy for Hodgkin's disease: long-term results.

Authors:  P Selby; P Patel; S Milan; M Meldrum; J Mansi; E Mbidde; M Brada; T Perren; G Forgeson; M Gore
Journal:  Br J Cancer       Date:  1990-08       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.